NCT00971334

Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,502 (actual)
• Sponsor: Sequenom, Inc. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to collect samples for the purpose of developing a prenatal aneuploid test using circulating cell free fetal (ccff) nucleic acid from blood samples from pregnant women who have a high-risk pregnancy undergoing invasive prenatal diagnosis by chorionic villus sampling (CVS) and/or genetic amniocentesis. The results of the ccff aneuploid test will be compared to the chromosomal analysis obtained via CVS or amniocentesis.

Conditions

• Pregnancy
• Aneuploidy
• Down Syndrome
• Edwards Syndrome

Timeline

• Start date: 2009-08-01
• Primary completion: 2011-09-01
• Completion: 2011-12-01
• First posted: 2009-09-03
• Last updated: 2012-02-17

Locations

35 sites across 2 countries: United States, France